{"pub": "breitbart", "url": "https://breitbart.com/news/poor-evidence-cannabis-improves-mental-health-study", "downloaded_at": "2019-10-28 23:37:32.799562+00:00", "title": "Poor evidence cannabis improves mental health: study", "language": "en", "text": "Paris (AFP) \u2013 People with psychiatric disorders may want to pass on the joint \u2014 at least until further research is done, a new Australian study suggests.\n\nThe paper, published Monday in The Lancet Psychiatry, looked at 83 previous studies conducted over almost four decades on medical cannabinoids, including products from the cannabis plant, such as leaves, buds and oils, as well as pharmaceutical-grade cannabinoids.\n\nThe authors found insufficient evidence that the products were safe and effective in treating six common disorders: depression, anxiety, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder and psychosis.\n\nCannabis and cannabinoids are increasingly being made available for medicinal use in North America, Britain and Australia without being subjected to the standard process that includes testing and scrutinising by government regulatory bodies, lead author Louisa Degenhardt told AFP.\n\n\u201cOne of the most striking things about the spread of legislation in multiple countries permitting cannabis/cannabinoids for medicinal purposes is that this is in many instances happening outside of the regulatory frameworks that medicine development typically occurs within,\u201d said Degenhardt, from the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney.\n\nThe study found that after chronic non-cancer pain, mental health is one of the most common reasons for using medicinal cannabinoids.\n\nBut no reviews have considered the varying effects of the different types of cannabinoids or their safety, and the only studies into long-term effects were conducted on individuals using cannabis for recreational use.\n\nIn most randomised-controlled trials of the effects of cannabinoids on depression and anxiety, the use was related to another condition, like chronic pain or multiple sclerosis.\n\nSome studies showed improvement in anxiety symptoms, but it was unclear if that effect was due to improvements in the primary condition.\n\nIn one small study of patients with psychosis, pharmaceutical THC \u2014 the active substance in cannabis \u2014 actually worsened symptoms.\n\n\u2013 Safety risks \u2013\n\nThere are safety concerns as well.\n\n\u201cThere are risks of developing dependence upon cannabis,\u201d said Degenhardt. \u201cThere are also risks if someone drives while intoxicated, and there [is] evidence that people who use cannabis regularly may be at increased risk of developing depression and psychotic symptoms.\u201d\n\nAlso, getting the drugs via the illicit market \u201ccarries risk of prosecution as well as unknown product content, quality and safety,\u201d added Tom Freeman, of the Addiction and Mental Health Group at the University of Bath.\n\nMedications that are proven to be effective and aren\u2019t addictive already exist for many of the conditions for which cannabis is being used, said Deepak Cyril D\u2019Souza, of Yale University School of Medicine\u2019s Department of Psychiatry, who wrote a commentary on the study.\n\nA large study \u2014 with a double-blind, randomised, placebo-controlled trial \u2014 is the gold standard for determining the balance between a drug\u2019s efficacy and its side effects, D\u2019Souza told AFP.\n\nUntil that is completed, \u201cone cannot have confidence in attributing any beneficial effects observed in a clinical trial to cannabis.\u201d", "description": "Paris (AFP) \u2013 People with psychiatric disorders may want to pass on the joint \u2014 at least until further research is done, a new Australian", "authors": [], "top_image": "https://media.breitbart.com/media/2019/10/wi/afp/28/ab64a9_cannabis-cannabinoids-are-increasingly-medicinal-use-in-north-america-640x335.jpg", "published_at": "2019-10-28"}